The aim of this study was to evaluate the expression of ERα and aromatase in tissue samples of glioblastoma patients and to have a closer look at the reaction of glioblastoma cell lines to a combined therapy with estrogen and Temozolomid (TMZ). The gene discussed is CYP19A1; the disease is glioblastoma.